Ann: Cantrixil last patient visit, page-3

Preliminary analysis shows one complete response (CR) and two partial responses

Median progression-free survival (PFS) for Part A was 5.5 months (n=9), versus thehistorical control of 3.4 months,

Growing body of data provides strong evidence that Cantrixil is clinically active in thisvery late-stage patient population

Safety profile consistent with prior experience: most common adverse events weregastrointestinal in nature and low-grade

Australian lead investigator, Associate Professor Jermaine Coward, commented

“despite recent progress in ovarian cancer, there remains an urgent need for new therapies.

The Cantrixil phase I study was conducted in a very late-stage patient population, with few effective treatment options.

In that context, my colleagues and I consider these data to be extremely promising.”


Cantrixil has been able to shrink tumours and delay disease progression, demonstrating a clinically meaningful benefit